BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
NICE backs Novartis' Adakveo via special channel despite 'high uncertainty' about cost, long-term efficacy | Fierce Pharma
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19 - Cytotherapy
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
ASCO: Gilead's Kite soars over Novartis' CAR-T turf with Tecartus win in type of leukemia | Fierce Pharma
Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
ASH: Gilead, Novartis tout long-term data for CAR-T slow starters Yescarta, Kymriah | Fierce Pharma
Manufacturing News of Note—Novartis to have Cell Therapies make Kymriah in Australia; Piramal Pharma expands API plant in Canada | Fierce Pharma
FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment - WSJ
ONCOLOGIC DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT Tisagenlecleucel (CTL019) for the TREATMENT OF PEDIATRIC AND YOUNG ADULT PA
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials: Molecular Therapy - Methods & Clinical Development
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
The biological basis and clinical symptoms of CAR-T therapy-associated toxicites | Cell Death & Disease
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
Can CAR-T and gene therapy cures really sustain biopharma? Not for all, analyst says | Fierce Pharma
CAR T-cell treatment pathway: From patient identification to long-term management - touchONCOLOGY
